An observational study in Cervical Cancer Screening, HPV Infections and Cervical Intraepithelial Neoplasia, sponsored by University Hospital, Geneva. Completed at 1 site in Cameroon. Open to female participants aged 50 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by University Hospital, Geneva · Observational
Cervical cancer remains a major cause of mortality in low- and middle-income countries, especially among women aged 50 years and older who are often under-screened. In post-menopausal women, the transformation zone is frequently not visible, which makes visual inspection with acetic acid (VIA) less reliable and limits access to adequate screening. Human papillomavirus (HPV) self-sampling offers a simple and acceptable primary screening method, but effective triage options for HPV-positive women in this age group remain limited.
This study aims to evaluate the feasibility and diagnostic performance of a screening strategy based on HPV self-sampling followed by Pap cytology triage among HPV-positive women aged 50 to 65 years in Cameroon. Approximately 500 women will be invited to perform self-HPV testing at the Mifi District Hospital. HPV-positive women will undergo Pap cytology, endocervical brushing and digital cervicography, and eligible participants will receive treatment with thermal ablation at Bafoussam Regional Hospital. Follow-up at 12 months will include repeat HPV testing, cytology, and endocervical brushing.
The primary outcome is the diagnostic accuracy of HPV + cytology triage for detecting CIN2+. Secondary outcomes include prevalence of high-risk HPV, treatment outcomes, acceptability, and adherence to follow-up.
Cervical cancer remains a leading cause of cancer-related mortality among women in low- and middle-income countries (LMICs), including Cameroon. Although most screening programs target women aged 30-49 years, approximately 40% of cervical cancer cases occur after the age of 50. Postmenopausal women face unique anatomical and physiological changes-particularly the regression of the squamocolumnar junction into the endocervical canal-that reduce the sensitivity of visual triage methods such as visual inspection with acetic acid (VIA). Evidence on optimal screening and triage strategies for women aged 50 years and older in LMIC settings is currently lacking.
This feasibility study aims to evaluate the diagnostic performance, acceptability, and clinical outcomes of a cervical cancer screening strategy based on high-risk human papillomavirus (hr-HPV) testing on self-collected vaginal samples, followed by cytology triage of HPV-positive postmenopausal women. The study also explores the added value of extended hr-HPV genotyping to refine risk stratification. The target population includes 500 women aged 50-65 years living in the Mifi Health District, West Cameroon.
At the first visit, eligible women will receive standardized information on cervical cancer and study procedures before providing written informed consent. Participants will then collect a self-obtained vaginal sample, which will be tested onsite using the GeneXpert platform for detection of all hr-HPV types. HPV-negative women will be advised to repeat screening after 5-10 years (or 3-5 years if HIV-positive). HPV-positive women will undergo clinician-collected Pap cytology and endocervical brushing (ECB). Cytology slides will be prepared using manual liquid-based cytology techniques, digitized using a portable whole-slide scanner, and interpreted remotely by trained cytopathologists. ECB samples will undergo histopathological evaluation and will constitute the diagnostic gold standard for assessing triage performance.
Women with cytology results ≥ASC-US will be referred for evaluation and treatment at Bafoussam Regional Hospital. A VIA/VILI examination will guide thermal ablation treatment using WHO-recommended devices and probes adapted to cervical anatomy. Cervical biopsies will be performed in the presence of suspicious lesions suggestive of high-grade disease or cancer. All treatments, follow-up assessments, and management of adverse events will be provided free of charge.
All HPV-positive participants, regardless of baseline cytology results, will be invited for a 12-month follow-up visit including repeat HPV testing, cytology, ECB, and VIA/VILI. Persistence of CIN2+ at 12 months will indicate the need for large loop excision of the transformation zone (LLETZ). Treatment adherence, side effects, and acceptability of the screening and treatment process will be assessed using structured questionnaires administered at baseline, post-treatment (4-6 weeks), and 12 months.
The primary outcomes include sensitivity, specificity, positive and negative predictive values, and likelihood ratios of cytology and extended genotyping (alone or combined) for detection of CIN2+ compared with ECB histology. Secondary outcomes include prevalence of hr-HPV infection and high-grade lesions, effectiveness of thermal ablation for CIN2+ clearance at 12 months, acceptability among women and healthcare providers, and adherence to all steps of the two-stage screening strategy.
This project is expected to generate essential evidence to guide cervical cancer screening policies for older women in LMICs, support the WHO global elimination initiative, and offer a scalable, context-adapted approach combining self-sampling, digital cytology, and appropriate treatment pathways.
576 studies on the registry are indexed under Papillomavirus Infections; 132 are open to participants now.
This study's enrollment of 500 is close to the median of 490 across 157 observational studies indexed under Papillomavirus Infections.
Browse Papillomavirus Infections studies →University Hospital, Geneva is the lead sponsor of 379 studies on the registry; 70 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The source population is the entire population of women aged between 50 and 65 years old in the Mifi health district.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women from the general population aged 50-65 years old eligible for screening in the West region of Cameroon. Inclusion criteria * Women aged 50 to 65 years old; * Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF). Exclusion criteria * Women who is pregnant; * Women with a condition that interfere with visualization of the cervix; * Women with vaginal bleeding outside the menstrual period; * Women who have had a total hysterectomy; * Women with a history of cervical cancer; * Women screened for cervical cancer in the last 5 years or in the last 3 years if HIV-positive; * Women in the terminal phase of an illness.
Diagnostic Test: Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators.
Women will perform a self-collected vaginal sample for the detection of high-risk human papillomavirus (HPV) DNA using a molecular assay (HPV DNA test). The sample will be collected using a sterile flocked swab and placed in a transport medium. Laboratory analysis will be conducted at the Mifi District Hospital using the GeneXpert HPV assay (Cepheid, USA). Women who test positive for high-risk HPV will undergo cytology triage (Pap test) and, if cytology is positive (≥ASC-US), will be offered thermal ablation at Bafoussam Regional Hospital.
Also known as: VIA/VILI, Pap smear, Cervical biopsy, Endo-cervical brushing, HPV test
Sensitivity and specificity of HPV test followed by cytology to detect cervical precancerous lesions in sub-Saharan Africa using histology as gold standard
To determine the diagnostic performance of screening strategies using HPV testing with cytology triage and/or extended genotyping in women aged between 50 and 65 years for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+);
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Dec 2024, 6 months.
Of 53 non-industry observational studies under Papillomavirus Infections, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 92. This study's 6 months is below that.
Counting every sponsor, half of 66 studies reached it within 46 months; a quarter within 24 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.